StreetInsider.com Pre-Open Movers 11/03
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Join SI Premium – FREE
StreetInsider.com Pre-Open Movers:
Shares of Neurocrine Biosciences, Inc. (Nasdaq: NBIX) 29% LOWER; the company now said the NDA for indiplon capsules is targeted to be resubmitted to the FDA during summer 2008. The company will conduct an additional 3-month safety and efficacy study for sleep onset to ensure the highest probability for the success of the resubmission.
Red Robin Gourmet (Nasdaq: RRGB) 27% LOWER; reports Q3 EPS of $0.47 (ex-items), 4 cents better than estimates.(0.43) Revenues were $148.6 million vs. $148.39 million consensus. Sees Q4 revenues between $156 million and $158 million and net income of $0.33 to $0.38 per diluted share. Current Q4 revenue consensus is $163.59 million and EPS consensus is $0.49. Sees FY06 revenues between $611 million and $613 million, and net income of between $1.62 and $1.67 per diluted share down from the previous revenue guidance of $615 million to $618 million, and net income of between $1.74 and $1.83. Current FY revenue consensus is $618.37 million and EPS consensus is $1.78.
Stellent, Inc. (Nasdaq: STEL) 25% HIGHER; announced a definitive agreement for Oracle (Nasdaq: ORCL) to acquire Stellent through a cash tender offer for $13.50 per share, or approximately $440 million.
Syntax-Brillian Corporation (Nasdaq: BRLC) 22% HIGHER; reports Q1 EPS of $0.07, 6 cents better than estimates.(0.01) Revenues were $87 million vs. $75.30 million consensus. Sees Q2 revenues between (ex-Vivitar) $160-170 million vs. $150 milllion consensus. Sees FY07 revenues (ex-Vivitar) between $490-520 million vs. $428 million consensus.
Whole Foods Market (Nasdaq: WFMI) 20% LOWER; reports Q3 EPS of $0.29, in-line with estimates.(0.29) Revenues were $1.29 billion vs. $1.32 billion consensus. For fiscal year 2007, on a 52-week to 52-week basis, the Company now expects total sales growth of 13% to 17%. Based on recent results, current sales trends and the continuing difficult comparisons, particularly in the first half of the year, the Company expects comparable store sales growth of 6% to 8% for fiscal year 2007.
LookSmart Ltd. (Nasdaq: LOOK) 19% HIGHER; reports In-Line Q3. Piper Jaffray upgrade
aQuantive (Nasdaq: AQNT) 15.3% LOWER; reports Q3 EPS of $0.16, in-line with estimates.(0.16) Revenues were $111 million vs. $112.57 million consensus. The company reiterates its anticipation of full-year 2006 results . Sees revenue of $420-$430 million, versus the consensus of $429.6 million. Sees net income of $0.54-$0.58 per diluted share, versus the consensus of $0.59. Multiple downgrades
Perini (NYSE: PCR) 14% HIGHER; reports Q3 EPS of $0.36, 6 cents better than estimates.(0.30) Revenues were $777.3 million vs. $709.58 million consensus. Sees FY07 EPS between $2.00-2.20 vs. $1.66 consensus.
LeapFrog Enterprises, Inc. (NYSE: LF) 15% LOWER; reported a Q3 net loss of $49.7 million, or ($0.79) per share, versus the consensus of a $0.34 profit. Net sales came in at $184.7 million versus the conensus of $218.3 million. The company is expecting a net loss per share of approximately $2.00 per share for 2006. The consensus is a $0.42 loss.
Encysive Pharmaceuticals (NASDAQ: ENCY) 13% HIGHER; submitted a complete response to the July 24, 2006 approvable letter for its New Drug Application for Thelin 100 mg tablets, a potential new oral treatment for pulmonary arterial hypertension.
Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) 8% HIGHER; Announces Progress in Cystic Fibrosis Program
Electronic Arts (Nasdaq: ERTS) 8% HIGHER; reports Q2 EPS of $0.07 ($0.21 ex-items) vs. consensus of $0.02. Revenues were $784 million vs. $672.53 million consensus. Sees Q3 EPS between $0.50-0.60 vs. consensus of $0.59. Sees Q3 revenues between $1.2-1.3 billion vs. $1.2 billion. Sees FY revenues between $2.95-3.125 billion vs. $2.94 billion consensus. Sees FY EPS between $0.55-0.70 vs. consensus of $0.56.
McDermott Int'l (NYSE: MDR) 8% HIGHER; reports Q3 EPS of $0.89, 30 cents better than estimates.(0.59) Revenues were $1.12 billion vs. $975.3 million consensus.
Powerwave (Nasdaq: PWAV) 8% LOWER; reports Q3 loss of $0.07 per share, ex-items, 4 cents worse than estimates. Revenues came in at $145.8 million versus the consensus of $155.9 million.
CA (NYSE: CA) 7% LOWER; reports Q2 EPS of $0.25, 5 cents better than estimates.(0.20) Revenues were $996 million vs. $969.41 million consensus. CA updated its outlook for the fiscal year 2007 and expects to meet or exceed revenue guidance of $3.9 billion and its original guidance for non-GAAP operating earnings per share of $0.83. Current FY07 revenue consensus is $3.91 billion and EPS consensus is $0.85.
SINA Corp (Nasdaq: SINA) 7% HIGHER; reports Q3 EPS of $0.25 (ex-items), 7 cent better than estimates.(0.18) Revenues were $56.1 million vs. $52.79 million consensus. Sees Q4 revenues between $53-56 million vs. $52.5 million consensus.
ViaCell Inc. (Nasdaq: VIAC) 6% HIGHER; UBS upgrades ViaCell from Reduce to Buy with a $6 price target.
Emmis Communications Corporation (Nasdaq: EMMS) 6% HIGHER; announced that its Board of Directors has declared a special cash dividend of $4 per share payable pro rata to all holders of the Company's common stock, with a record date of Sunday, Nov. 12, 2006 and a payment date of Wednesday, Nov. 22, 2006.
JDS Uniphase (Nasdaq: JDSUD) 6% HIGHER; reports Q1 EPS of $0.03, 2 cents better than estimates.(0.01) Revenues were $318.1 million vs. $321.59 million consensus. For the second quarter of fiscal 2007, ending December 31, 2006, the Company expects net revenue of $332 to $352 million. Current consensus is $342 milllion.
Intevac Inc. (NASDAQ: IVAC) 4% HIGHER; will replace Wolverine Tube Inc. (NYSE: WLV) in the S&P SmallCap 600 after the close of trading on Monday, November 6.
THQ Inc. (Nasdaq: THQI) 3.5% HIGHER; reports Q2 earnings of $0.19 per share, versus the consensus of $0.03. Revenues came in at $240.2 million versus the consensus of $201 million. Sees Q3 EPS of $0.73-$0.78 versus the consensus of $0.97. Sees Q3 revenues of $400-$425 million versus the consensus of $429 million. Sees FY07 EPS of $1.13-$1.23 versus the consensus of $0.95. Sees FY07 revenues of $925-$975 million versus the consensus of $943.1 million.
Fidelity National Information Services Inc. (NYSE: FIS) 2.5% HIGHER; S&P 500 constituent Louisiana-Pacific Corp. (NYSE: LPX) will replace Fidelity National Information Services Inc. (NYSE: FIS) in the S&P MidCap 400, Fidelity National Information Services Inc. will replace Louisiana-Pacific Corp. in the S&P 500.
Nuveen Investments Inc. (NYSE: JNC) 2.3% HIGHER; will replace Fidelity National Financial Inc. (NYSE: FNF) in the S&P MidCap 400 after the close of trading on Thursday, November 9.
Crocs (Nasdaq: CROX) 2% HIGHER; reports Q3 EPS of $0.53, 12 cents better than estimates.(0.41) Revenues were $111 million vs. $92.19 million consensus. Sees FY EPS between $1.50-1.53 vs. consensus of $1.26. Sees FY revenues between $334-337 million vs. $301.8 million consensus.
Shares of Neurocrine Biosciences, Inc. (Nasdaq: NBIX) 29% LOWER; the company now said the NDA for indiplon capsules is targeted to be resubmitted to the FDA during summer 2008. The company will conduct an additional 3-month safety and efficacy study for sleep onset to ensure the highest probability for the success of the resubmission.
Red Robin Gourmet (Nasdaq: RRGB) 27% LOWER; reports Q3 EPS of $0.47 (ex-items), 4 cents better than estimates.(0.43) Revenues were $148.6 million vs. $148.39 million consensus. Sees Q4 revenues between $156 million and $158 million and net income of $0.33 to $0.38 per diluted share. Current Q4 revenue consensus is $163.59 million and EPS consensus is $0.49. Sees FY06 revenues between $611 million and $613 million, and net income of between $1.62 and $1.67 per diluted share down from the previous revenue guidance of $615 million to $618 million, and net income of between $1.74 and $1.83. Current FY revenue consensus is $618.37 million and EPS consensus is $1.78.
Stellent, Inc. (Nasdaq: STEL) 25% HIGHER; announced a definitive agreement for Oracle (Nasdaq: ORCL) to acquire Stellent through a cash tender offer for $13.50 per share, or approximately $440 million.
Syntax-Brillian Corporation (Nasdaq: BRLC) 22% HIGHER; reports Q1 EPS of $0.07, 6 cents better than estimates.(0.01) Revenues were $87 million vs. $75.30 million consensus. Sees Q2 revenues between (ex-Vivitar) $160-170 million vs. $150 milllion consensus. Sees FY07 revenues (ex-Vivitar) between $490-520 million vs. $428 million consensus.
Whole Foods Market (Nasdaq: WFMI) 20% LOWER; reports Q3 EPS of $0.29, in-line with estimates.(0.29) Revenues were $1.29 billion vs. $1.32 billion consensus. For fiscal year 2007, on a 52-week to 52-week basis, the Company now expects total sales growth of 13% to 17%. Based on recent results, current sales trends and the continuing difficult comparisons, particularly in the first half of the year, the Company expects comparable store sales growth of 6% to 8% for fiscal year 2007.
LookSmart Ltd. (Nasdaq: LOOK) 19% HIGHER; reports In-Line Q3. Piper Jaffray upgrade
aQuantive (Nasdaq: AQNT) 15.3% LOWER; reports Q3 EPS of $0.16, in-line with estimates.(0.16) Revenues were $111 million vs. $112.57 million consensus. The company reiterates its anticipation of full-year 2006 results . Sees revenue of $420-$430 million, versus the consensus of $429.6 million. Sees net income of $0.54-$0.58 per diluted share, versus the consensus of $0.59. Multiple downgrades
Perini (NYSE: PCR) 14% HIGHER; reports Q3 EPS of $0.36, 6 cents better than estimates.(0.30) Revenues were $777.3 million vs. $709.58 million consensus. Sees FY07 EPS between $2.00-2.20 vs. $1.66 consensus.
LeapFrog Enterprises, Inc. (NYSE: LF) 15% LOWER; reported a Q3 net loss of $49.7 million, or ($0.79) per share, versus the consensus of a $0.34 profit. Net sales came in at $184.7 million versus the conensus of $218.3 million. The company is expecting a net loss per share of approximately $2.00 per share for 2006. The consensus is a $0.42 loss.
Encysive Pharmaceuticals (NASDAQ: ENCY) 13% HIGHER; submitted a complete response to the July 24, 2006 approvable letter for its New Drug Application for Thelin 100 mg tablets, a potential new oral treatment for pulmonary arterial hypertension.
Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) 8% HIGHER; Announces Progress in Cystic Fibrosis Program
Electronic Arts (Nasdaq: ERTS) 8% HIGHER; reports Q2 EPS of $0.07 ($0.21 ex-items) vs. consensus of $0.02. Revenues were $784 million vs. $672.53 million consensus. Sees Q3 EPS between $0.50-0.60 vs. consensus of $0.59. Sees Q3 revenues between $1.2-1.3 billion vs. $1.2 billion. Sees FY revenues between $2.95-3.125 billion vs. $2.94 billion consensus. Sees FY EPS between $0.55-0.70 vs. consensus of $0.56.
McDermott Int'l (NYSE: MDR) 8% HIGHER; reports Q3 EPS of $0.89, 30 cents better than estimates.(0.59) Revenues were $1.12 billion vs. $975.3 million consensus.
Powerwave (Nasdaq: PWAV) 8% LOWER; reports Q3 loss of $0.07 per share, ex-items, 4 cents worse than estimates. Revenues came in at $145.8 million versus the consensus of $155.9 million.
CA (NYSE: CA) 7% LOWER; reports Q2 EPS of $0.25, 5 cents better than estimates.(0.20) Revenues were $996 million vs. $969.41 million consensus. CA updated its outlook for the fiscal year 2007 and expects to meet or exceed revenue guidance of $3.9 billion and its original guidance for non-GAAP operating earnings per share of $0.83. Current FY07 revenue consensus is $3.91 billion and EPS consensus is $0.85.
SINA Corp (Nasdaq: SINA) 7% HIGHER; reports Q3 EPS of $0.25 (ex-items), 7 cent better than estimates.(0.18) Revenues were $56.1 million vs. $52.79 million consensus. Sees Q4 revenues between $53-56 million vs. $52.5 million consensus.
ViaCell Inc. (Nasdaq: VIAC) 6% HIGHER; UBS upgrades ViaCell from Reduce to Buy with a $6 price target.
Emmis Communications Corporation (Nasdaq: EMMS) 6% HIGHER; announced that its Board of Directors has declared a special cash dividend of $4 per share payable pro rata to all holders of the Company's common stock, with a record date of Sunday, Nov. 12, 2006 and a payment date of Wednesday, Nov. 22, 2006.
JDS Uniphase (Nasdaq: JDSUD) 6% HIGHER; reports Q1 EPS of $0.03, 2 cents better than estimates.(0.01) Revenues were $318.1 million vs. $321.59 million consensus. For the second quarter of fiscal 2007, ending December 31, 2006, the Company expects net revenue of $332 to $352 million. Current consensus is $342 milllion.
Intevac Inc. (NASDAQ: IVAC) 4% HIGHER; will replace Wolverine Tube Inc. (NYSE: WLV) in the S&P SmallCap 600 after the close of trading on Monday, November 6.
THQ Inc. (Nasdaq: THQI) 3.5% HIGHER; reports Q2 earnings of $0.19 per share, versus the consensus of $0.03. Revenues came in at $240.2 million versus the consensus of $201 million. Sees Q3 EPS of $0.73-$0.78 versus the consensus of $0.97. Sees Q3 revenues of $400-$425 million versus the consensus of $429 million. Sees FY07 EPS of $1.13-$1.23 versus the consensus of $0.95. Sees FY07 revenues of $925-$975 million versus the consensus of $943.1 million.
Fidelity National Information Services Inc. (NYSE: FIS) 2.5% HIGHER; S&P 500 constituent Louisiana-Pacific Corp. (NYSE: LPX) will replace Fidelity National Information Services Inc. (NYSE: FIS) in the S&P MidCap 400, Fidelity National Information Services Inc. will replace Louisiana-Pacific Corp. in the S&P 500.
Nuveen Investments Inc. (NYSE: JNC) 2.3% HIGHER; will replace Fidelity National Financial Inc. (NYSE: FNF) in the S&P MidCap 400 after the close of trading on Thursday, November 9.
Crocs (Nasdaq: CROX) 2% HIGHER; reports Q3 EPS of $0.53, 12 cents better than estimates.(0.41) Revenues were $111 million vs. $92.19 million consensus. Sees FY EPS between $1.50-1.53 vs. consensus of $1.26. Sees FY revenues between $334-337 million vs. $301.8 million consensus.
You May Also Be Interested In
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- Tesla shares fall as Deutsche Bank flags risks from focus on Robotaxi
- L'Oreal sales rise 9.4% as mass market makeup outshines luxury
Create E-mail Alert Related Categories
General News, Special ReportsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
